10% Owner HHLR ADVISORS sells 17.84M shares of BGNE at $200.00 for $3.6B, reducing stake by 12.5%
HHLR ADVISORS, LTD. divested 17,842,500 shares at $200.00, reducing holdings from 142.89M to 125.05M shares—a -12.5% reduction of its prior position. At the transaction price of $200.00, the stock stood between its 30-day change of -3.9% and 90-day change of +3.9%, and 19.1% below the 52-week high of $246.04. Prior sells by this insider at BGNE showed mixed timing outcomes: 3 of 5 prior sales were well-timed (stock fell after), while 2 of 5 were poorly timed (stock rose after). The company is unprofitable on a full-year basis (net income $-121.4M) despite strong annual revenue growth of +73.6%, creating a backdrop where large equity transfers by major holders merit attention. The sale's size and price point relative to recent range and historical timing patterns provide material data points for assessing shareholder concentration and insider behavior at this capital-intensive biotech issuer.